Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Tapentadol Hydrochloride

    Client Email Product

    Tapentadol Hydrochloride

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    32
    US DMFs Filed

    US DMFs Filed

    5
    CEP/COS Certifications

    CEP/COS Certifications

    2
    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    9
    Other Suppliers

    Other Suppliers

    24
    API REF. PRICE (USD / KG)
    443

    API Market Place

    24
    INTERMEDIATES
    2
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    30
    Europe

    Europe

    70
    Canada

    Canada

    8
    Australia

    Australia

    5
    South Africa

    South Africa

    5
    Uploaded Dossiers

    Uploaded Dossiers

    53
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    808.00

    Annual Reports

    0

    FDF Market Place

    2
    EXCIPIENTS
    180
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    34

    USFDA Exclusivities

    4
    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    28
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET, EXTENDED RELEASE;ORAL - EQ 100MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 150MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 250MG BASE
    • TABLET, EXTENDED RELEASE;ORAL - EQ 50MG BASE
    • SOLUTION;ORAL - EQ 20MG BASE/ML
    • TABLET;ORAL - EQ 100MG BASE
    • TABLET;ORAL - EQ 50MG BASE
    • TABLET;ORAL - EQ 75MG BASE
    Full View ScreenFull Screen View
    Two painkillers Tapentadol and Pregabalin may go off OTC over misuse
    Two painkillers Tapentadol and Pregabalin may go off OTC over misuse

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/two-painkillers-tapentadol-and-pregabalin-may-go-off-otc-over-misuse/articleshow/105482448.cms

    ECONOMIC TIMES
    25 Nov 2023
    Share Share
    Alkem's Generic Tapentadol Receives Approval in the U.S.
    Alkem's Generic Tapentadol Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205016

    FDA
    07 Jul 2023
    Share Share
    Recall of Palexia® oral solution 20mg/ml and Palexia® 4 mg/ml oral solution
    Recall of Palexia® oral solution 20mg/ml and Palexia® 4 mg/ml oral solution

    https://www.grunenthal.com/en/press-room/statements/media-statement-recall-of-palexia-oral-solution

    PRESS RELEASE
    08 Feb 2021
    Share Share
    Restrict use of pain reliever Tapentadol: Child rights panel urges government
    Restrict use of pain reliever Tapentadol: Child rights panel urges government

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/restrict-use-of-pain-reliever-tapentadol-child-rights-panel-urges-government/articleshow/78009939.cms

    T. Thacker ECONOMIC TIMES
    08 Sep 2020
    Share Share
    Grünenthal GmbH v. Alkem Labs. Ltd.
    Grünenthal GmbH v. Alkem Labs. Ltd.

    https://www.jdsupra.com/legalnews/grunenthal-gmbh-v-alkem-labs-ltd-38458/

    JDSUPRA
    28 Mar 2020
    Share Share
    Collegium to acquire U.S. rights to Nucynta from Assertio for $375M
    Collegium to acquire U.S. rights to Nucynta from Assertio for $375M

    https://www.bioworld.com/articles/432936-collegium-to-acquire-us-rights-to-nucynta-from-assertio-for-375m?v=preview

    Michael Fitzhugh BIOWORLD
    27 Feb 2020
    Share Share
    Palexia SR 100 mg tapentadol sustained release tablets
    Palexia SR 100 mg tapentadol sustained release tablets

    https://www.tga.gov.au/alert/palexia-sr-100-mg-tapentadol-sustained-release-tablets

    TGA
    14 Feb 2020
    Share Share
    Collegium Announces Closing of the Nucynta Franchise Acquisition
    Collegium Announces Closing of the Nucynta Franchise Acquisition

    https://www.globenewswire.com/news-release/2020/02/13/1984889/0/en/Collegium-Announces-Closing-of-the-Nucynta-Franchise-Acquisition.html

    GLOBENEWSWIRE
    13 Feb 2020
    Share Share
    Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharma
    Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharma

    https://www.globenewswire.com/news-release/2020/02/06/1981407/0/en/Assertio-Therapeutics-Announces-Sale-of-NUCYNTA-Franchise-to-Collegium-Pharmaceutical-for-375-0-Million.html

    GLOBENEWSWIRE
    06 Feb 2020
    Share Share
    Union Quimico Farmaceutica Fails EDQM Inspection
    Union Quimico Farmaceutica Fails EDQM Inspection

    https://www.pharmacompass.com/pdf/news/union-quimico-farmaceutica-fails-edqm-inspection-1572404101.pdf

    EDQM
    29 Oct 2019
    Share Share
    Beset by lawsuits and criticism in U.S., opioid makers eye new market in India
    Beset by lawsuits and criticism in U.S., opioid makers eye new market in India

    https://www.fiercepharma.com/pharma/beset-by-lawsuits-and-criticism-u-s-opioid-makers-eye-new-market-india

    Sarah Varney FIERCE PHARMA
    31 Aug 2019
    Share Share
    Johnson & Johnson opioid trial judge expected to issue landmark verdict Monday
    Johnson & Johnson opioid trial judge expected to issue landmark verdict Monday

    https://www.cnbc.com/2019/08/22/johnson-johnson-opioid-trial-judge-to-issue-landmark-verdict.html

    Berkeley Lovelace Jr. CNBC
    23 Aug 2019
    Share Share
    Nucynta® (tapentadol): Purdue Pharma v. Collegium NF
    Nucynta® (tapentadol): Purdue Pharma v. Collegium NF

    https://www.pharmacompass.com/pdf/news/nucynta-tapentadol-purdue-pharma-v-collegium-nf-1518418339.pdf

    PATENT LITIGATION
    07 Feb 2018
    Share Share
    Troubled Depomed sells off Nucynta, axes 40% of workforce
    Troubled Depomed sells off Nucynta, axes 40% of workforce

    https://www.fiercepharma.com/pharma/troubled-depomed-sells-off-nucynta-axes-40-workforce-to-pare-down-costs

    Carly Helfand FIERCE PHARMA
    05 Dec 2017
    Share Share
    Depomed wins Nucynta patent fight, but does that harm or help in proxy battle?
    Depomed wins Nucynta patent fight, but does that harm or help in proxy battle?

    http://www.fiercepharma.com/pharma/depomed-wins-nucynta-patent-fight-but-does-harm-or-help-proxy-fight

    Eric Palmer FIERCE PHARMA
    03 Sep 2016
    Share Share
    Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review
    Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review

    http://www.prnewswire.com/news-releases/depomed-announces-patent-trial-and-appeal-board-denial-of-inter-partes-review-of-nucynta-patent-300300058.html

    PR NEWSWIRE
    18 Jul 2016
    Share Share
    Did Depomed’s Citizen Petition for Nucynta ER Strategically Backfire?
    Did Depomed’s Citizen Petition for Nucynta ER Strategically Backfire?

    http://twofourinsight.com/did-depomed-citizen-petition-nucynta-er-strategically-backfire/

    TWOFOUR INSIGHT
    05 May 2016
    Share Share
    Grunenthal Denied Indian Patent Use of Tapentadol to Treat Osteoarthritis Pain
    Grunenthal Denied Indian Patent Use of Tapentadol to Treat Osteoarthritis Pain

    http://twofourinsight.com/grunenthal-denied-indian-patent-use-tapentadol-treat-osteoarthritis-pain/

    TWOFOUR INSIGHT
    27 Jan 2016
    Share Share
    Depomed isn't anti-takeover, CEO says. It was just anti-Horizon
    Depomed isn't anti-takeover, CEO says. It was just anti-Horizon

    http://www.fiercepharma.com/story/depomed-isnt-anti-takeover-ceo-says-it-was-just-anti-horizon/2016-01-13

    Carly Helfand FIERCE PHARMA
    13 Jan 2016
    Share Share
    Horizon drops hostile takeover attack on Depomed after legal ruling
    Horizon drops hostile takeover attack on Depomed after legal ruling

    http://www.fiercepharma.com/story/horizon-drops-hostile-takeover-attack-depomed-after-legal-ruling/2015-11-20

    Eric Palmer FIERCE PHARMA
    20 Nov 2015
    Share Share
    Depomed Acquires U.S. Rights, First-in-Class Pain Product from Grunenthal
    Depomed Acquires U.S. Rights, First-in-Class Pain Product from Grunenthal

    http://www.prnewswire.com/news-releases/depomed-acquires-us-rights-to-late-stage-first-in-class-pain-product-from-grunenthal-300180429.html

    PR NEWSWIRE
    17 Nov 2015
    Share Share
    Depomed's staffed-up Nucynta salesforce starts bringing home the bacon
    Depomed's staffed-up Nucynta salesforce starts bringing home the bacon

    http://www.fiercepharmamarketing.com/story/depomeds-staffed-nucynta-salesforce-starts-bringing-home-bacon/2015-11-16

    Carly Helfand FIERCE PHARMA MARKETING
    16 Nov 2015
    Share Share
    Depomed Issues Statement on Horizon Pharma plc's Unsolicited Exchange Offer
    Depomed Issues Statement on Horizon Pharma plc's Unsolicited Exchange Offer

    http://www.prnewswire.com/news-releases/depomed-issues-statement-on-horizon-pharma-plcs-unsolicited-exchange-offer-300138965.html

    PR NEWS WIRE
    08 Sep 2015
    Share Share
    Actavis' Generic Tapentadol Receives Tentative Approval in US For Pain
    Actavis' Generic Tapentadol Receives Tentative Approval in US For Pain

    https://www.pharmacompass.com/pdf/news/n69.pdf

    FDA
    20 May 2015
    Share Share
    Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.
    Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.

    http://www.prnewswire.com/news-releases/janssen-pharmaceuticals-inc-completes-divestiture-of-us-license-rights-to-nucynta-tapentadol-nucynta-er-tapentadol-extended-release-tablets-and-nucynta-tapentadol-oral-solution-to-depomed-inc-300060522.html

    PR NEWSWIRE
    02 Apr 2015
    Share Share
    Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
    Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

    http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-newsArticle&ID=2032117&highlight=

    Press Release DEPOMED
    02 Apr 2015
    Share Share
    J&J s Pain Drug is Depomed s Gain in 1 05 Billion Deal
    J&J s Pain Drug is Depomed s Gain in 1 05 Billion Deal

    http://www.bloomberg.com/news/2015-01-15/j-j-s-pain-drug-is-depomed-s-gain-in-1-05-billion-deal.html

    Drew Armstrong BLOOMBERG
    16 Jan 2015
    Share Share
    Shire CEO Extends Deal Drive with $5.2B NPS Pharma Buyout
    Shire CEO Extends Deal Drive with $5.2B NPS Pharma Buyout

    http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=1052

    Tracy Staton FIERCE PHARMA
    11 Jan 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search